Tafenoquine succinate inhibits the growth of the equine piroplasmosis hemoparasites Theileria equi and Babesia caballi

Key Points

• Inhibition of T. equi and B. caballi growth demonstrates tafenoquine's potential as an alternative therapy.
• Significant reductions in hemoparasite proliferation observed at doses safe for equine PBMCs.
• Assessment using equine peripheral blood mononuclear cells (PBMCs) highlights the treatment's effectiveness.
• Supports further research on tafenoquine for in vivo applications in treating equine piroplasmosis.